The higher concentrations of mangiferin (10, 25 or 50 μM) with doxorubicin for 96 h have the ability to re-sensitize MCF-7 breast cancer cellsthrough reducing cell viability and inhibiting P-glycoprotein (P-gp) expression [46]. The gene discussed is ABCB1; the disease is breast carcinoma.